We have postulated since 1993 that Type 2 diabetes and its cardiovascular mortality were both predominantly due to obesity. Five major trials in the last century have failed to show any cardiovascular benefit from glucose control. Now landmark studies just presented in Amsterdam (Holland), at American Heart Association Scientific Sessions, and in the New England Journal of Medicine showed a 20% relative-risk reduction in cardiovascular events in obese patients with and without type 2 diabetes who were treated with the weight-loss drug semaglutide – who also lost significant weight -as compared with the control group.
Leave a Reply